MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Apomorphine"

  • 2017 International Congress

    Efficacy of sublingual apomorphine film (APL-130277) for the treatment of OFF episodes in patients with Parkinson’s disease:  results from the Phase 3 study dose-titration phase

    R. Hauser, S. Isaacson, A. Espay, R. Pahwa, D. Truong, E. Pappert, P. Gardzinski, B. Dzyngel, A. Agro, H. Fernandez (Tampa, FL, USA)

    Objective: To determine the dose of APL-130277 required by each patient with Parkinson’s Disease (PD) to turn from OFF to Full ON.  This dose is…
  • 2017 International Congress

    Safety of sublingual apomorphine film (APL-130277) for the treatment of OFF episodes in patients with Parkinson’s disease: Preliminary Results from a Phase III Study

    S. Isaacson, R. Hauser, A. Espay, R. Pahwa, D. Truong, E. Pappert, P. Gardzinksi, B. Dzyngel, A. Agro, H. Fernandez (Boca Raton, FL, USA)

    Objective: To determine the safety of single treatments of APL-130277 in patients with Parkinson’s disease (PD).  Background: Patients with Parkinson’s disease (PD) frequently develop problematic…
  • 2017 International Congress

    Disease severity is not predictive of the dose required for apomorphine sublingual film (APL-130277) to convert a patient with Parkinson’s disease(PD) from OFF to fully ON: Preliminary Results from a Phase III Study

    H. Fernandez, S. Isaacson, A. Espay, R. Pahwa, D. Truong, E. Pappert, P. Gardzinski, B. Dzyngel, A. Agro, R. Hauser (Cleveland, OH, USA)

    Objective: To determine if baseline disease severity could be correlated to the effective dose of APL-130277 that was required to turn a patient with PD…
  • 2017 International Congress

    ND0701: A new concentrated formulation of Apomorphine for continuous subcutaneous administration – human PK data

    L. Adar, C. Durlach, O. Yacoby Zeevi, D. Fishelovitch, S. Oren (Rehovot, Israel)

    Objective: To evaluate the PK and relative bioavailability of ND0701, a subcutaneously (SC) infused apomorphine-base product candidate, and a commercial apomorphine-HCl product. The secondary objective…
  • 2017 International Congress

    Pharmaeconomic study of the treatment of advanced Parkinson’s disease.

    F. VIVANCOS-MATELLANO, A. SANZ, J.U. MIRÓ, J. CADAVID, A. RUÍZ, N. SOLER (Madrid, Spain)

    Objective: Conduct a comparative pharmacoeconomic analysis of the use of  subcutaneous apomorphine infusion pump (SAIP),   continuous levodopa/carbidopa duodenal infusión (LDI) and deep brain stimulation (DBS). Background:…
  • 2017 International Congress

    Alternative Apomorphine Challenge Test

    J.C. Martinez Castrillo, A. Alonso Canovas, C. Estevez Fraga, G. Sanchez Diez, I. Avilés Olmos, J. Lopez Sendon, P. Garcia Ruiz, L. Vela Desojo (Madrid, Spain)

    Objective: To propose a new apomorphine challenge test Background: In the standard apomorphine challenge test, the appropriate dose of apomorphine is established by incremental dosing…
  • 2017 International Congress

    The efficacy of continuous apomorphine infusion in advanced PD patients with cognitive impairments

    R. Borgemeester, T. van Laar (Groningen, Netherlands)

    Objective: To review the outcome of continuous apomorphine infusion (CAI) in advanced Parkinson’s disease (PD) patients at the rehabilitation unit of the Parkinson Expertise Center…
  • 2017 International Congress

    Effects of continuous apomorphine infusion on motor and nonmotor symptoms in Parkinson’s disease without cognitive deterioration

    J.-F. Houvenaghel, S. Drapier, J. Duprez, D. Drapier, M. Vérin (Rennes, France)

    Objective: The aim of the present study was to investigate the influence of apomorphine pump in Parkinson’s disease (PD) on motor and nonmotor symptoms, including…
  • 2017 International Congress

    Stimulation in the nucleus entopeduncularis affects neuronal activity in the nucleus accumbens and medial prefrontal cortex after apomorphine-induced deficient prepulse inhibition in rats

    K. Schwabe, J. Krauss, M. Alam (Hannover, Germany)

    Objective: The aim of our study was to investigate the effects of stimulation in the rat entopeduncular nucleus (EPN) on single neuronal activity of the…
  • 2016 International Congress

    PERFORM: Controlled study in fluctuating PD patients examining the effects of motor state on the outcomes resulting from a structured physical therapy (PT) program

    J.P. Hubble, B. Fisher, K. Lyons, C. McLean, G. Petzinger, R. Pahwa (Louisville, KY, USA)

    Objective: To determine if outcomes following a PT program are improved if PT sessions are conducted while PD patients are in an on motor state…
  • « Previous Page
  • 1
  • …
  • 9
  • 10
  • 11
  • 12
  • 13
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley